TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A post hoc analysis of a randomized trial found that older adults assigned to eat walnuts daily had about 6% higher total IgG after two years than those in the control group. The study did not establish that this change improves immunity or prevents cardiovascular disease, and walnut consumption did not significantly affect the other measured immune markers.
A two-year analysis of the randomized Walnuts and Healthy Aging (WAHA) trial found that older adults assigned to eat walnuts daily had about 6% higher total IgG concentrations than participants in the control group. The findings were reported in JACC Advances. The analysis measured immune biomarkers; it did not show that the increase improved health, strengthened protection against infection or reduced cardiovascular events.
According to the JACC Advances report, the analysis used data from the Walnuts and Healthy Aging (WAHA) trial, which enrolled 708 cognitively healthy adults aged 63 to 79 in the United States and Spain. Participants were assigned either to add 30–60 grams of walnuts a day to their diet or to avoid walnuts for two years. The analysis examined blood samples collected at the start and end of the trial from 474 participants: 240 in the walnut group and 234 controls.
The researchers measured total immunoglobulin G and M (IgG and IgM), antibodies directed at MDA-modified LDL, and circulating MDA-LDL. After accounting for baseline levels and other factors, the report found total IgG was approximately 6% higher across the two study sites in the walnut group than in controls. The difference was larger in U.S. participants, at 11%; the researchers did not find a statistically significant intervention effect in Spain.
The report found no significant difference between the groups for the other main markers. Walnut consumption did not significantly change total IgM, MDA-LDL, or MDA-LDL-specific IgM or IgG antibodies compared with the control diet. Total IgG and IgM, along with MDA-LDL-specific IgM, declined over time within both groups. These within-group changes do not by themselves show that walnuts caused the changes.
What the IgG Difference Can Tell Us
IgG is a class of antibody involved in the body’s humoral immune response. As the WAHA analysis measured blood biomarkers rather than clinical outcomes, a higher concentration is a biomarker finding, not proof that the immune system is working better. The study did not test whether participants experienced fewer infections, responded differently to vaccines, or had better clinical outcomes because of the measured change.
The question also matters to cardiovascular research. Atherosclerosis involves plaque buildup and inflammation, and immune responses to modified LDL are being studied for possible roles in that process. The authors noted that prior research has linked some antibody measures with cardiovascular outcomes, but findings for MDA-LDL-specific IgG have been inconsistent. The WAHA analysis found no significant walnut-related change in those specific antibodies and did not assess whether walnut consumption prevented heart disease.
Products Worth Considering
BowFlex Results Series SelectTech Dumbbells
Oura Ring 4 Smart Ring – Silver – Size 8
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
As an affiliate, we earn on qualifying purchases.
How the WAHA Trial Was Set Up
The original WAHA trial was designed to examine cognitive function and retinal integrity, rather than immune biomarkers, according to the report. The current work is a post hoc analysis of blood samples from a subset of trial participants. That distinction matters: the immune results address questions explored after the main trial was planned, and the analysis does not establish a clinical benefit from the IgG difference.
The report says participants were recruited in the United States and Spain between May 2012 and May 2014. People who regularly ate more than two servings of tree nuts each week, or used certain supplements including fish oil and flaxseed oil, were excluded. Follow-up visits took place every two months. In Spanish participants, red blood cell alpha-linolenic acid levels rose substantially in the walnut group and fell in controls, a finding the researchers used as support for adherence to the assigned diets.
The study sites differed at baseline: total IgG and IgM levels were 25% lower among U.S. participants than Spanish participants. Other characteristics also varied between centers. The researchers adjusted their models for factors including age, sex, smoking, cholesterol, body mass index, hypertension and diabetes; the report says sensitivity analyses produced similar overall findings.
What the Study Cannot Establish
The WAHA report does not show why the IgG levels differed or whether the difference has any meaningful effect on health. The analysis did not establish a mechanism, identify a beneficial IgG threshold, or connect the biomarker change to fewer illnesses or cardiovascular events. The clinical implications remain uncertain, as the report itself states.
The result also varied by location: the U.S. subgroup showed an 11% difference, while no statistically significant effect was detected in Spain. Baseline immune-marker levels differed between the sites, and the analysis included fewer participants than the full 708-person trial. The findings therefore should not be read as evidence that walnuts reliably raise IgG in every population or in people outside the study’s age and health profile.
The source report does not provide a confidence interval or a detailed account of the size and direction of every adjusted estimate, so the precision of the reported effects cannot be independently described here. The study also does not show whether the result would persist beyond two years.
Questions for Future Walnut Research
The JACC Advances report describes a biomarker analysis rather than a new clinical recommendation. Further research would need to test whether the IgG association is reproducible, clarify why the effect differed between the U.S. and Spanish groups, and determine whether any change in antibody concentration relates to health outcomes that matter to patients.
Readers should not interpret the finding as evidence that walnuts treat immune conditions or prevent cardiovascular disease. The WAHA trial tested a specific diet in selected older adults, and its immune analysis did not measure those benefits. The next step is additional research linking dietary changes and immune markers to clinical outcomes, rather than assuming that a higher laboratory value is beneficial.
Key Questions
What did the walnut study find?
In a two-year analysis of the WAHA trial reported in JACC Advances, participants assigned to eat walnuts daily had about 6% higher total IgG than controls across the U.S. and Spanish study sites. The analysis found no significant walnut-related difference in total IgM, MDA-LDL, or the measured MDA-LDL-specific antibodies.
Does higher IgG mean stronger immunity?
Not necessarily. IgG is an antibody measure, but the WAHA analysis did not test whether the higher concentration improved protection against infection, vaccine response or other clinical outcomes. The health meaning of the difference is uncertain.
Did walnuts lower cardiovascular risk in the study?
The WAHA analysis did not show that walnuts reduced heart attacks, atherosclerosis or other cardiovascular outcomes. It assessed immune-related blood markers, and walnut consumption did not significantly change the measured MDA-LDL-specific antibodies compared with the control diet.
How much did participants eat?
Those assigned to the walnut diet were asked to consume 30–60 grams daily, equivalent to about 15% of their daily energy intake, according to the trial report. The results apply to the trial’s selected group of adults aged 63 to 79 and cannot automatically be generalized to everyone.
Source: news-medical.net
